Latest Middle East News

SRJ Technologies has completed the first phase of its growth strategy and is now advancing into market penetration with a significant $23.8 million joint venture in the Middle East and a key board appointment.

Champion Iron Limited reported robust Q3 FY2026 results with record sales and ongoing progress on its DRPF project, while launching a significant acquisition offer for Rana Gruber.

Change Financial Limited has reported a record revenue quarter driven by its Vertexon platform growth and new client wins, prompting an upgrade to its FY26 financial guidance.

icetana Limited reported steady growth in Q2 FY26 with a 36% increase in annual recurring revenue and expanded partnerships across APAC and the Middle East. The company’s cash flow improved, while product enhancements aim to strengthen its AI security offerings.

Imricor Medical Systems has achieved multiple world-first procedures using real-time MRI guidance for cardiac ablation, advancing clinical trials and regulatory progress amid a strategic commercial expansion.

Streamplay Studio Limited has reported a third consecutive cash-flow positive quarter, driven by the blockbuster launch of Winter Burrow and key Tier-1 platform partnerships including Amazon. The company’s diversified publishing and subscription model underpins a robust financial position heading into 2026.

Eden Innovations has significantly reduced its debt burden and secured fresh capital, while expanding sales and trials of its advanced concrete additives across key international markets.

Firebrick Pharma has commenced commercial manufacturing and export of its new Nasodine Throat Spray, marking a significant step in its international expansion. The company also reported a 15% increase in cash sales and reduced operating costs, signalling improving financial health.

Elsight Limited capped 2025 with record quarterly revenue and a substantial US$21.2 million contract, signalling robust growth and expanding global defence engagements heading into 2026.

Electro Optic Systems (EOS) reports a record $459 million contract backlog, major new defence contracts including a $120 million laser weapon deal, and a strategic acquisition to boost counter-drone capabilities.

Cambium Bio has strengthened its financial footing with a $0.6 million R&D tax refund and a $2.4 million strategic placement, setting the stage for pivotal Phase 3 clinical trials of its lead ophthalmology candidate.

Memphasys Limited has achieved its first material revenues following CE Mark approval for its Felix™ System, activating multi-year contracts across Europe, the Middle East, and Asia. The company is now transitioning from regulatory preparation to global commercial rollout with a focus on recurring revenues.